

## Trypsin-induced biphasic regulation of tone in the porcine lower esophageal sphincter

田中, 義将

<https://doi.org/10.15017/1543935>

---

出版情報：九州大学, 2015, 博士（医学）, 課程博士  
バージョン：  
権利関係：やむを得ない事由により本文ファイル非公開（2）



# **Trypsin-induced biphasic regulation of tone in the porcine lower esophageal sphincter**

Yoshimasa Tanaka<sup>1</sup>, Eikichi Ihara<sup>1</sup>, Katsuya Hirano<sup>2</sup>, Shunsuke Takahashi<sup>3</sup>, Mayumi Hirano<sup>2</sup>, Kazuhiko Nakamura<sup>1</sup>, Hirotada Akiho<sup>1</sup>, Yoshinao Oda<sup>3</sup> and Ryoichi Takayanagi<sup>1</sup>

<sup>1</sup>Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

<sup>2</sup>Division of Molecular Cardiology, Research Institute of Angiocardiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

<sup>3</sup>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

## **Address correspondence to:**

Eikichi Ihara, M.D., Ph.D.

Department of Medicine and Bioregulatory Science

Graduate School of Medical Sciences, Kyushu University

3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Tel: +81-92-642-5286; Fax +81-92-642-5287

E-mail: [eikichi@intmed3.med.kyushu-u.ac.jp](mailto:eikichi@intmed3.med.kyushu-u.ac.jp)

**Abbreviations:** LES, lower esophageal sphincter; GERD, Gastro-esophageal reflux disease; ROK, Rho-associated protein kinase; PAR, proteinase-activated receptor; PKC, protein kinase C; ERK, extracellular signal-activated protein kinase; p38MAPK, p38 MAP kinase; NES, normal extracellular solution; 118-KES, 118mM K<sup>+</sup> extracellular solution; p-APMSF, p-amidinophenyl methanesulfonyl fluoride; AP, activating peptide; L-NAME, N<sup>o</sup>-nitro-L-arginine methyl ester.

## **Abstract**

The lower esophageal sphincter (LES) plays an important role in coordinated esophageal motility. The present study aimed to elucidate how trypsin affects LES contractility. Porcine LES circular smooth muscle strips were prepared. Contractile responses to trypsin were assessed. Trypsin (300 nM) induced a transient contraction. At concentrations of 1  $\mu$ M or higher, trypsin induced biphasic responses, consisting of a transient contraction followed by a transient relaxation. Pretreatment with either 1  $\mu$ M tetrodotoxin or carbenoxolone had no effect on these responses. In contrast, trypsin-induced responses were completely blocked by pretreatment with the serine protease inhibitor. Pretreatment with 10  $\mu$ M FSLLRY-NH<sub>2</sub>, a PAR<sub>2</sub> antagonist, significantly inhibited trypsin-induced biphasic responses. Trypsin (1  $\mu$ M)-induced contractions were partially inhibited by pretreatment with 10  $\mu$ M Y-27632. In addition, trypsin (10  $\mu$ M)-induced relaxation was partially inhibited by pretreatment with 10  $\mu$ M Y-27632, 10  $\mu$ M PD98059 or 10  $\mu$ M SB203580. Trypsin-induced relaxation was abolished by increasing the extracellular K<sup>+</sup> concentration to 40 mM, but not by pretreatment with L-arginine methyl ester. Furthermore, trypsin-induced relaxation was partially inhibited by pretreatment with 10  $\mu$ M glibenclamide or 1  $\mu$ M 4-aminopyridine. Trypsin causes biphasic regulation of LES tone by directly acting on smooth muscle. Rho-associated protein kinase (ROK) is involved in trypsin-induced contraction, whereas ROK, ERK1/2, p38MAPK, and membrane hyperpolarization are involved in relaxation. The regulation of LES tone by trypsin may play a role in esophageal motility.

**Keywords:** Esophageal motility; Trypsin; Proteinase-activated receptors; Gastro-esophageal Reflux Disease; Smooth muscle

## 1. Introduction

Trypsin exerts various cellular effects by activating proteinase-activated receptors (PARs), a unique family of G protein-coupled receptors (Cocks et al., 1999). Among the four PAR subtypes, PAR<sub>1</sub>, PAR<sub>2</sub> and PAR<sub>4</sub> are potential receptors for trypsin (Cocks et al., 1999). PARs are expressed in smooth muscle cells and/or their adjacent cells throughout the gastrointestinal tract and PARs modulate the contractility of gastrointestinal smooth muscle (Kawabata et al., 2008). The Ca<sup>2+</sup>-dependent phosphorylation of the regulatory light chain of myosin II plays a fundamental role in the contraction of smooth muscle (Pfitzer, 2001). Trypsin activation of PAR<sub>2</sub> induces Ca<sup>2+</sup> signaling and activation of several protein kinases, including protein kinase C (PKC), Rho-associated protein kinase (ROK), extracellular signal-activated protein kinase (ERK) 1/2 and p38 MAP kinase (p38MAPK) (Adams et al., 2011). All of these signals conceivably contribute to the effect of trypsin on gastrointestinal smooth muscle contraction. PKC, ROK, ERK1/2 and p38MAPK are known to inhibit the activity of myosin light chain phosphatase, thus contributing to smooth muscle contraction (Eto et al., 1995; Ihara et al., 2007; Kimura et al., 1996). Regulation of gastrointestinal contractility by trypsin/PARs has been reported in stomach, small intestine and colon (Cocks et al., 1999; Kawabata et al., 1999; Mule et al., 2002). However, limited information is available regarding the regulatory role of trypsin in the function of esophagus.

It has been reported that the level of PAR<sub>2</sub> expression is up-regulated in the esophageal mucosa of patients with gastro-esophageal reflux disease (GERD) and correlates with pathological characteristics of GERD (Kandulski et al., 2010). The activation of PAR<sub>2</sub> by trypsin induces the secretion of interleukin 8, which may contribute to impairment of epithelial barrier function in patients with GERD (Kandulski et al., 2010; Shan et al., 2012;

Yoshida et al., 2007). Although it seems that trypsin also plays important roles in esophageal function, it remains to be determined how trypsin affects esophageal motility.

The present study thus aimed to investigate the effects of trypsin on the esophageal motility, by focusing on how trypsin affects the contractility of the lower esophageal sphincter (LES), using preparations of LES circular smooth muscle isolated from porcine esophagus and endeavored to elucidate the underlying mechanisms since LES plays a key role in coordinated esophageal motility. We demonstrate, for the first time, that trypsin causes a unique biphasic response in the porcine LES, composed of an initial transient contraction and a subsequent relaxation. The present study also demonstrates a major contribution of PAR<sub>2</sub> to the trypsin-induced biphasic regulation and provides evidence for the mechanisms underlying these effects.

## **2. Materials and Methods**

### *2.1 Tissue preparation*

The section of the porcine esophagus containing the esophagogastric junction was freshly obtained from a local slaughterhouse and immediately transported to our laboratory in normal extracellular solution (NES). The specimen was cut open in the longitudinal direction along the greater curvature of the stomach and pinned, mucosal side up, to the flat surface of a silicone rubber plate. After removing the mucosal layer, the circular smooth muscle sheets of the LES were excised and cut into strips (2 mm × 5 mm) under a binocular microscope.

### *2.2. Measurement of force produced by LES circular smooth muscle strips*

The LES circular smooth muscle strips were mounted vertically to a TB-612T force transducer (Nihon Koden, Tokyo, Japan) in a 5 ml organ bath containing NES, and the

measurement of isometric force in the strips was performed at 37°C. During the equilibration period, strips were first stretched to 1.3-fold resting length and were then stimulated with 118 mM K<sup>+</sup> extracellular solution (118-KES) every 10 min. The resting level of force spontaneously and gradually increased ( $2.185 \pm 0.392$  mN) during the equilibration period and then declined to a steady level ( $0.921 \pm 0.255$  mN). During the equilibration period, the contractile response to 118-KES also gradually increased with repeated stimulation, while a steady response was obtained within 2 h. All experimental protocols were then initiated. The extent of force development is expressed in mN, with zero being assigned to the resting level of force just prior to the initiation of the experimental protocols.

### *2.3. Immunohistochemistry of PAR<sub>2</sub> in LES circular smooth muscle*

A segment of the porcine esophagus containing the LES was fixed and embedded in paraffin. Paraffin-embedded sections, 4 µm thick, were prepared. Sections were deparaffinized in xylene, and rehydrated in ascending dilutions of ethanol. The samples were incubated overnight at 4°C with anti-PAR<sub>2</sub> antibody (1:50 dilution) in PBS containing 3% non-fat dried milk. For a negative control, the overnight incubation was performed without primary antibody. After a 40-min incubation at room temperature with a horseradish peroxidase-conjugated secondary antibody, the sections were developed with 3-3'-diaminobenzidine, and counterstained with hematoxylin.

### *2.4. Solutions and drugs*

The composition of NES was (in mM): 137.4 NaCl, 5.9 KCl, 1.2 CaCl<sub>2</sub>, 1.2 MgCl<sub>2</sub>, 11.5 glucose, and 11.6 HEPES, pH 7.3. KES was prepared by replacing NaCl with equimolar KCl. All chemicals were reagent grade unless otherwise indicated. Trypsin, thrombin, tetrodotoxin,

GF109203x, chelerythrine, apamin, iberiotoxin, glibenclamide, 4-aminopyridine (4-AP) and p-amidinophenylmethanesulfonyl fluoride (p-APMSF) were obtained from Sigma (St. Louis, MO, USA). TFLLR-NH<sub>2</sub> (PAR<sub>1</sub>-AP; PAR<sub>1</sub>-activating peptide), SLIGRL-NH<sub>2</sub> (mouse PAR<sub>2</sub>-AP), SLIGKV-NH<sub>2</sub> (human PAR<sub>2</sub>-AP), AYPGKF-NH<sub>2</sub> (PAR<sub>4</sub>-AP), and FSLLRY-NH<sub>2</sub> (PAR<sub>2</sub> antagonist) were purchased from Bachem (Bubendorf, Switzerland). AC-264613 was purchased from Tocris (Bristol, UK). ENMD-1068 was purchased from Abcam (Cambridge, UK). Y27632 and SB203580 were purchased from Calbiochem (San Diego, CA, USA). PD98059 and H1152 were purchased from Cayman Chemical (Boston, MA, USA). SCH79797 and anti-PAR<sub>2</sub> monoclonal antibody (SAM11) were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). N<sup>ω</sup>-nitro-L-arginine methyl ester (L-NAME) was obtained from Wako Pure Chemical Industries (Osaka, Japan).

## *2.5. Data analysis*

All data are expressed as the mean  $\pm$  S.E.M. Student's *t*-test was used to determine statistical significance between two groups. An analysis of variance followed by Dunnett's test was used to determine statistical significance between more than two groups. A value of  $P < 0.05$  was considered to be significant.



### 3. Results

#### *3.1. Effects of trypsin on the tone of porcine LES circular smooth muscle*

Trypsin, at concentrations up to 100 nM, had no effects on the tone of the LES circular smooth muscle (Fig. 1C). At 300 nM, trypsin induced a transient contraction. At concentrations of 1  $\mu$ M and higher, the relaxant effect became apparent and trypsin induced a biphasic response consisting of a transient contraction and a subsequent transient relaxation (Fig. 1A and C). An apparent maximal contractile response was observed at 1  $\mu$ M trypsin ( $0.747 \pm 0.088$  mN, n=16). At this concentration, the force peaked  $3.17 \pm 0.41$  min (n=16) after initiating trypsin stimulation (Fig. 1A). At concentrations higher than 1  $\mu$ M, the level of contraction obtained with 3  $\mu$ M and 10  $\mu$ M was smaller than that obtained with 1  $\mu$ M (Fig. 1C). However, the time to the peak contraction ( $1.88 \pm 0.22$  min, n=11) seen with 10  $\mu$ M trypsin was significantly shorter than that obtained with 1  $\mu$ M (Fig. 1A and B). On the other hand, trypsin-induced relaxation increased in a concentration-dependent manner at concentrations of 1  $\mu$ M and higher. An apparent maximal relaxant effect was obtained with 10  $\mu$ M trypsin ( $-0.699 \pm 0.106$  mN, n=15). With 10  $\mu$ M trypsin, the level of force reached a minimal level during the relaxation phase,  $9.97 \pm 0.84$  min (n=11) after initiating stimulation (Fig. 1B).

Pretreatment with 1  $\mu$ M tetrodotoxin had no effects on the spontaneous change in resting force, or on the trypsin-induced contraction and relaxation responses (data not shown). Pretreatment with carbenoxolone, an inhibitor of gap junction, also had no effects on trypsin-induced contractile and relaxant responses (data not shown). These observations exclude major contributions of the enteric nervous system and the interstitial cells of Cajal on the contractile and relaxant effects of trypsin in the LES circular smooth muscle.

Furthermore, trypsin, at concentrations up to 10  $\mu$ M, did not affect the following contractile

responses to 118-KES depolarization or carbachol, thus ruling out the contribution of cytotoxic effect to the trypsin-induced contractile and relaxant responses.

### *3.2. Involvement of PAR<sub>2</sub> in the trypsin-induced response of porcine LES circular smooth muscle*

Proteinase activity is a prerequisite for the involvement of PARs in proteinase-induced cellular effects. When trypsin was pretreated with 100  $\mu$ M p-APMSF, a serine protease inhibitor, both contractile and relaxant effects of trypsin were abolished (Fig. 2A). We next examined which PARs are involved in trypsin-induced responses. PAR<sub>1</sub>-AP (TFLLR-NH<sub>2</sub>) induced a substantial contraction ( $3.018 \pm 0.735$  mN, n=5) at a concentration of 100  $\mu$ M. However, pretreatment with 10  $\mu$ M SCH79797, a PAR<sub>1</sub> antagonist, had no inhibitory effects on this contraction ( $2.822 \pm 1.235$  mN, n=4) (Fig. 2D). Thrombin, an endogenous PAR<sub>1</sub> agonist, had no contractile or relaxant effects, up to 10 U/ml (data not shown). Moreover, pretreatment with 10  $\mu$ M SCH79797, a PAR<sub>1</sub> antagonist, had no inhibitory effects on trypsin (10  $\mu$ M)-induced contraction and relaxation (Fig. 2E). Therefore, the involvement of PAR<sub>1</sub> in the trypsin-induced responses is unlikely. Second, two PAR<sub>2</sub>-APs, SLIGRL-NH<sub>2</sub> and SLIGKV-NH<sub>2</sub>, induced significant contraction. The levels of contraction obtained with 100  $\mu$ M SLIGRL-NH<sub>2</sub> ( $0.225 \pm 0.118$  mN, n=4) and 100  $\mu$ M SLIGKV-NH<sub>2</sub> ( $0.274 \pm 0.118$  mN, n=4) were similar to those obtained with 300 nM trypsin (Fig. 1C), but lower than those obtained with 1  $\mu$ M trypsin (Fig. 2D). The level of contraction obtained with 1 mM SLIGKV-NH<sub>2</sub> ( $0.813 \pm 0.267$  mN, n=4) was equivalent to that ( $0.747 \pm 0.088$  mN, n=16) obtained with 1  $\mu$ M trypsin (Fig. 2B and D). However, PAR<sub>2</sub>-APs did not induce relaxation, even at 1 mM. Thus, we further investigated the effects of AC-264613 (a non-peptide PAR<sub>2</sub> agonist). Application of 1  $\mu$ M AC-264613 induced significant contraction ( $0.147 \pm 0.028$  mN,

n=4) similar to that seen with SLIGRL-NH<sub>2</sub> and SLIGKV-NH<sub>2</sub>. However, AC-264613 induced no apparent relaxation, as was the case with SLIGRL-NH<sub>2</sub> and SLIGKV-NH<sub>2</sub>. In contrast, pretreatment with 10  $\mu$ M FSLLRY-NH<sub>2</sub> (a peptide PAR<sub>2</sub> antagonist) partially but significantly inhibited not only contraction but also relaxation induced by 10  $\mu$ M trypsin. However, pretreatment with 5 mM ENMD-1068 (a non-peptide PAR<sub>2</sub> antagonist) did not inhibit contraction or relaxation induced by 10  $\mu$ M trypsin (Fig. 2C and E). Finally, PAR<sub>4</sub>-AP (AYPGKF-NH<sub>2</sub>) induced no response in LES circular smooth muscle (Fig. 2D). These results suggest that PAR<sub>2</sub> is involved in the trypsin-induced responses. Indeed, immunohistochemical analysis revealed expression of PAR<sub>2</sub> in LES circular smooth muscle and the mucosa in the region of the LES (Fig. 2F). These positive signals were abolished in the absence of the primary antibody (Fig. 2G).

### *3.3. Contribution of Rho kinase to trypsin-induced contraction of LES circular smooth muscle*

The maximal contractile response with a modest relaxation was induced by 1  $\mu$ M trypsin (Fig. 1C); therefore, the mechanisms of trypsin-induced contraction were investigated at this concentration. The application of 10  $\mu$ M Y-27632, a Rho kinase inhibitor, induced a significant reduction of the resting force, which gradually reached a new steady state level ( $-0.686 \pm 0.098$  mN, n=7) within 10 min (Fig. 3A and G). Subsequent stimulation with 1  $\mu$ M trypsin in the presence of 10  $\mu$ M Y-27632 induced a net development of force ( $0.225 \pm 0.069$  mN, n=7), which was significantly smaller than the control ( $0.747 \pm 0.088$  mN, n=16) (Fig. 3A and H). Similar results were obtained with 1  $\mu$ M H-1152, another inhibitor of Rho kinase (Fig. 3B, G and H). Y-27632 and H-1152 reduced the contractile effect of 1  $\mu$ M trypsin by 69.7% (n=7) and 67.1% (n=6), respectively. On the other hand, PD98059 (a MEK1/2 inhibitor), SB203580 (a p38MAPK inhibitor), GF109203x (a PKC inhibitor) and

chelerythrine (a PKC inhibitor) had no significant effect on either the resting force or trypsin-induced contraction (Fig. 3C–H).

#### *3.4. Involvement of membrane hyperpolarization in trypsin-induced relaxation of LES circular smooth muscle*

The maximal relaxant effect was induced by 10  $\mu$ M trypsin (Fig. 1C); therefore, the mechanism of relaxation was investigated at this concentration (Fig. 4). The application of 100  $\mu$ M L-NAME significantly enhanced the contractile response to 118-KES by 30 % (data not shown); however, it had no effect on the resting level of force. Subsequent stimulation with 10  $\mu$ M trypsin induced a biphasic response of initial contraction followed by relaxation (Fig. 4A). The extent of both contraction ( $0.666 \pm 0.195$  mN,  $n=5$ ; data not shown) and relaxation ( $-0.902 \pm 0.314$  mN,  $n=5$ ; Fig. 4C and D) did not significantly differ from those obtained in the absence of L-NAME. On the other hand, stimulation with 40-KES induced an initial phasic contraction, followed by a sustained contraction ( $0.745 \pm 0.182$  mN,  $n=5$ ; Fig. 4). The addition of 10  $\mu$ M trypsin during the 40-KES-induced sustained contraction caused a small transient contraction, but no relaxation (Fig. 4A). This results suggests the involvement of  $K^+$  channels in the trypsin-induced relaxation.

The absence of the relaxant effect of trypsin during 40-KES stimulation could be due to the increased level of force caused by 40-KES. Therefore, the effects of several  $K^+$  channel blockers on trypsin-induced relaxation were investigated. The application of 10  $\mu$ M glibenclamide (an ATP-sensitive  $K^+$  channel blocker), 1 mM 4-aminopyridine (a voltage-gated  $K^+$  channel blocker), or 1  $\mu$ M apamin (a small conductance  $Ca^{2+}$ -activated  $K^+$  channel blocker) had no significant effect on the resting level of force. However, 100 nM iberiotoxin (a large conductance  $Ca^{2+}$ -activated  $K^+$  channel blocker) significantly decreased

the resting level. Glibenclamide and 4-aminopyridine, but not apamin or iberiotoxin, significantly attenuated the trypsin-induced relaxation (Fig. 4D). The net decreases in force induced by 10  $\mu$ M trypsin in the presence of glibenclamide ( $-0.157 \pm 0.088$  mN, n=5) or 4-aminopyridine ( $-0.127 \pm 0.088$  mN, n=4) were significantly smaller than that seen in the absence of K<sup>+</sup> channel blockers (Fig. 4D).

### *3.5. Effects of Rho kinase, ERK1/2 and p38MAPK inhibitors on trypsin-induced relaxation in LES circular smooth muscle*

The effects of Rho kinase, MEK1 and p38MAPK inhibitors on the biphasic response to 10  $\mu$ M trypsin were examined, mainly to elucidate the mechanism of trypsin-induced relaxation (Fig. 5 and 6). The application of 10  $\mu$ M Y-27632 or 1  $\mu$ M H-1152, but not 10  $\mu$ M PD98059, 10  $\mu$ M SB203580, 10  $\mu$ M GF109203x or 10  $\mu$ M chelerythrine, substantially decreased the resting level of force (Fig. 5). Subsequent stimulation with 10  $\mu$ M trypsin induced a significant contraction in the presence of all kinase inhibitors (Fig. 5 and 6A). The extent of the net development of contraction obtained in the presence of kinase inhibitors was not significantly different from that obtained in their absence (Fig. 6A). These observations were in clear contrast to those shown in Fig. 3, where 10  $\mu$ M Y-27632 and 1  $\mu$ M H-1152 substantially suppressed the development of force induced by 1  $\mu$ M trypsin.

In contrast, the trypsin-induced relaxation was inhibited by pretreatment with 10  $\mu$ M Y-27632, 1  $\mu$ M H-1152, 10  $\mu$ M SB203580 or 10  $\mu$ M PD98059 (Fig. 5 and 6B). The net decreases in force seen in the presence of Y-27632 ( $-0.196 \pm 0.078$  mN, n=7), H-1152 ( $-0.216 \pm 0.069$  mN, n=6), PD98059 ( $-0.206 \pm 0.139$  mN, n=7) or SB203580 ( $-0.078 \pm 0.206$  mN, n=5) were significantly smaller than those seen in their absence (Fig. 6B). The

pre-treatment with 10  $\mu$ M GF109203x or 10  $\mu$ M chelerythrine had no significant effect on the relaxation induced by 10  $\mu$ M trypsin (Fig. 6B).

#### 4. Discussion

The present study demonstrates, for the first time, that trypsin uniquely regulates the tone of the porcine LES. Trypsin caused a biphasic response consisting of an initial transient contraction and a subsequent relaxation. The relaxant effect appeared to require higher concentrations of trypsin compared with those required for the contractile effect. Therefore, the relaxant response was not evident at 1  $\mu$ M and lower concentrations, while the biphasic response was apparent at concentrations higher than 1  $\mu$ M. The observations with tetrodotoxin and carbenoxolone suggest a negligible contribution from the nervous system and the interstitial cells of Cajal to both contractile and relaxant effects of trypsin. Both contractile and relaxant effects of trypsin thus appear to be attributable to a myogenic response. A trypsin-induced biphasic response was also reported in the mouse gastric fundus (Cocks et al., 1999) and small intestine (Kawabata et al., 1999; Sekiguchi et al., 2006). In these studies, the biphasic responses consisted of an initial relaxation followed by a contraction and the relaxant effects were observed at lower concentrations than those required for the contractile effects. In one study (Liu et al., 2010), the contractile effect was partly dependent on the release of contractile neurotransmitters from capsaicin-sensitive nerves, while in another study (Huang, 2007), it was shown to be resistant to tetrodotoxin. The myogenic biphasic regulation with initial contraction followed by relaxation thus appears to be unique to the LES.

Both contractile and relaxant effects of trypsin were abolished by pretreatment with a protease inhibitor. This observation is consistent with the involvement of PARs in both effects. PAR<sub>1</sub>, PAR<sub>2</sub>, and PAR<sub>4</sub> are potential receptors for trypsin, while PAR<sub>1</sub> and PAR<sub>4</sub> are also activated by thrombin (Hollenberg et al., 1997). Thrombin had neither contractile nor relaxant effects. No contractile or relaxant effects were observed for PAR<sub>4</sub>-AP. However, a PAR<sub>1</sub>-AP,

TFLLR-NH<sub>2</sub>, induced significant contraction, but this contraction was resistant to a PAR<sub>1</sub> antagonist, SCH79797. Therefore, the contractile response seen with PAR<sub>1</sub>-AP may not be mediated by PAR<sub>1</sub>, but it could be a non-canonical effect. A similar SCH79797-resistant and, therefore, non-canonical effect of TFLLR-NH<sub>2</sub> has been reported in rat myometrium (Aman et al., 2005). Moreover, a PAR<sub>1</sub> antagonist had no inhibitory effects on trypsin-induced responses. Therefore, any major involvement of PAR<sub>1</sub> or PAR<sub>4</sub> in the contractile and relaxant effects of trypsin is unlikely.

Accordingly, PAR<sub>2</sub> is the only receptor among the PARs, which is responsible for trypsin-induced responses. In fact, the expression of PAR<sub>2</sub> was detected by immunohistochemistry in LES circular smooth muscle (Fig. 2F). Both PAR<sub>2</sub>-APs (peptide PAR<sub>2</sub> agonists) and AC-264613 (a non-peptide PAR<sub>2</sub> agonist) consistently induced a contractile response. However, no relaxant effects were observed with these non-protease agonists at concentrations up to 1 mM for PAR<sub>2</sub>-APs and 1 μM for AC-264613. The effects of higher concentrations of non-protease PAR<sub>2</sub> agonists were not investigated because of a technical limitation. The extent of contraction and the contraction pattern induced by non-protease PAR<sub>2</sub> agonists were similar to those seen with 300 nM trypsin. At this concentration, trypsin induced no apparent relaxation (Fig. 1C). It is therefore possible that the potency of non-protease PAR<sub>2</sub> agonists was too weak to replicate both the contractile and relaxant effects of trypsin. However, the possibility that the relaxant effect of trypsin is not mediated by PAR<sub>2</sub> cannot be ruled out. In contrast, a PAR<sub>2</sub> antagonist, FSLLRY-NH<sub>2</sub>, partially but significantly inhibited not only contraction but also relaxation induced by 10 μM trypsin. This observation suggests the involvement of PAR<sub>2</sub> in both the contractile and relaxant effects of trypsin. It has been reported that FSLLRY-NH<sub>2</sub> blocks PAR<sub>2</sub> activation induced by trypsin by interfering with the interaction of the tethered ligand to its docking site



on PAR<sub>2</sub>, but not by inhibition of trypsin to cleave PAR<sub>2</sub> (Al-Ani et al., 2002). Therefore, the results obtained with FSLLRY-NH<sub>2</sub> might support the involvement of PAR<sub>2</sub> in both the contractile and relaxant effects of trypsin. However, the observations with a non-peptide antagonist, ENMD-1068, might cause some controversy for the role of PAR<sub>2</sub> in the trypsin-induced effects. There is a concern regarding the potency of ENMD-1068 because its IC<sub>50</sub> is approximately 3 mM (Lohman et al., 2012), and 5 mM ENMD-1068 was used in the present study. Taken together, the observations obtained with agonists and antagonists appear to provide a suggestive indication but not fully convincing support for the involvement of PAR<sub>2</sub> in the trypsin-induced contraction and relaxation of porcine LES circular smooth muscle. Alternatively, a PAR<sub>2</sub>-independent mechanism could be involved in this process. Specifically, trypsin cleavage might produce peptide agonists that indirectly mediate the contractile and/or relaxant effects of trypsin. This mechanism might be consistent with the fact that relatively high concentrations of trypsin were required to elicit contractile and relaxant effects in the present study. However, the requirement for high concentrations of trypsin might be attributable to the expression of serine protease inhibitors (serpins) in the porcine LES. In fact, some serpins are expressed in the esophagus (Strik et al., 2002).

The contractile effect of trypsin was maximal at 1  $\mu$ M, with minimal accompanying relaxation (Fig. 1A). The mechanisms of trypsin-induced contraction were therefore investigated using this contraction. Two chemically different ROK inhibitors, Y27632 and H1152, similarly and substantially inhibited the contraction induced by 1  $\mu$ M trypsin. ROK inhibitors also decreased the resting level of tension. However, inhibitors of PKC, MEK1 and p38MAPK exerted no significant effect on either the resting level of tension or the contraction induced by trypsin. These observations suggest that ROK plays an important role in the trypsin-induced contraction and in maintenance of the resting tone in the LES. It is also

possible that the inhibition of the contractile effect of trypsin was due to the suppression of the resting tension, but not due to inhibition of contractile mechanism activated by trypsin. The observations of the present study are therefore consistent with those of a previous study, regarding the involvement of ROK in the maintenance of spontaneous tone in the cat LES (Harnett et al., 2005). However, the observations of the present study are inconsistent with those of a previous study, which showed a major role of PKC, ERK1/2 and p38MAPK in the acetylcholine-induced contraction of the circular smooth muscle of the cat LES (Cao et al., 2003).

The mechanisms of trypsin-induced relaxation were examined at 10  $\mu$ M, which induced maximal relaxation. NO plays a central role in the vagal nerve-mediated relaxation of the LES in various species (Paterson et al., 1992). The effect of L-NAME and 40 mM  $K^+$  suggest that the trypsin-induced myogenic relaxation is mainly attributable to membrane hyperpolarization. Furthermore, the inhibitory effects of glibenclamide and 4-aminopyridine suggest a major contribution of ATP-sensitive  $K^+$  channels and voltage-gated  $K^+$  channels to the trypsin-induced relaxation in the porcine LES. PAR<sub>2</sub>-mediated relaxation has been shown to be mainly dependent on apamin-sensitive, small conductance  $Ca^{2+}$ -activated  $K^+$  channels in mouse gastric fundus (Cocks et al., 1999), guinea pig colon (Cocks et al., 1999) and rat colon (Mule et al., 2002). There was, however, variation in the type of  $K^+$  channel that mediates the trypsin-induced relaxation depending on the species and the type of gastrointestinal tract. The trypsin-induced relaxation was greatly suppressed by pre-treatment with Y27632, H1152, PD98059, or SB203580, indicating that  $K^+$  channels, ERK1/2, p38MAPK, and ROK contribute to trypsin-induced relaxation.

The regulation of LES tone by trypsin/PAR<sub>2</sub> signaling pathway in the present study may have clinical relevance in GERD. GERD is defined as a condition, in which reflux of

stomach contents causes clinical symptoms, including heartburn and regurgitation as well as complications such as Barrett's esophagus and reflux esophagitis (Vakil et al., 2006). Not only acid reflux but also non-acid reflux contributes to the development of GERD symptoms (Vakil et al., 2006). Reflux of duodenal juices with trypsin into the esophagus is one of the major mechanisms for non-acid reflux (Orel and Vidmar, 2007; Vaezi and Richter, 1996). It was shown that trypsin concentration in pure pancreatic juice was nearly 40 mM in normal healthy subjects (Fedail et al., 1979). Especially it was reported that up to 26 % of patients with partial gastrectomy developed GERD symptoms and that trypsin concentration in esophagus was increased up to 428 mM (Gotley et al., 1992). Therefore, it is quite possible that reflux of trypsin into esophagus induces biphasic regulation of LES tone via activation of PAR<sub>2</sub>, as observed in the present study. Although trypsin/PAR<sub>2</sub> signaling pathway is suggested to play a role in pathogenesis and pathophysiology of GERD (Kandulski et al., 2010; Souza, 2010), the pathophysiological roles of trypsin/PAR<sub>2</sub> in the regulation of LES tone thus remain to be elucidated in GERD patients.

In conclusion, trypsin induces a unique regulation of tone mainly by activating PAR<sub>2</sub> in the circular smooth muscle of the porcine LES. Trypsin exerts a contractile effect at lower concentrations than those required for the relaxant response, thus causing a biphasic response consisting of initial contraction and subsequent relaxation at concentrations higher than 1  $\mu$ M. ROK is suggested to contribute to both contractile and relaxant responses, while ERK1/2 and p38MAPK contribute to the relaxant effect. The trypsin-induced relaxation is mediated by ATP-sensitive K<sup>+</sup> channels and voltage-gated K<sup>+</sup> channels. A trypsin/PAR<sub>2</sub> signaling pathway would be a potential new target for the treatment of esophageal motility disorders including GERD patients.

**Acknowledgements and funding:**

This work was supported in part by Grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology and by AstraZeneca Research Support.

**Disclosures:** The authors have no conflict of interest to disclose with respect to this manuscript.

**Author contributions:**

Y.T., E.I. and K.H. designed this study and mainly wrote the manuscript. Y.T. carried out physiological experiments. S.T. and Y.O. carried out pathological experiments. M.H., K.N. and H.A. provided technical and material supports. R.T. supervised this study.

## References

- Adams, M.N., Ramachandran, R., Yau, M.K., Suen, J.Y., Fairlie, D.P., Hollenberg, M.D., Hooper, J.D., 2011. Structure, function and pathophysiology of protease activated receptors. *Pharmacol Ther* 130, 248-282.
- Al-Ani, B., Saifeddine, M., Wijesuriya, S.J., Hollenberg, M.D., 2002. Modified proteinase-activated receptor-1 and -2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin. *J Pharmacol Exp Ther* 300, 702-708.
- Cao, W., Sohn, U.D., Bitar, K.N., Behar, J., Biancani, P., Harnett, K.M., 2003. MAPK mediates PKC-dependent contraction of cat esophageal and lower esophageal sphincter circular smooth muscle. *Am J Physiol Gastrointest Liver Physiol* 285, G86-95.
- Cocks, T.M., Sozzi, V., Moffatt, J.D., Selemidis, S., 1999. Protease-activated receptors mediate apamin-sensitive relaxation of mouse and guinea pig gastrointestinal smooth muscle. *Gastroenterology* 116, 586-592.
- Eto, M., Ohmori, T., Suzuki, M., Furuya, K., Morita, F., 1995. A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. *J Biochem* 118, 1104-1107.
- Fedail, S.S., Harvey, R.F., Salmon, P.R., Brown, P., Read, A.E., 1979. Trypsin and lactoferrin levels in pure pancreatic juice in patients with pancreatic disease. *Gut* 20, 983-986.
- Gotley, D.C., Ball, D.E., Owen, R.W., Williamson, R.C., Cooper, M.J., 1992. Evaluation and surgical correction of esophagitis after partial gastrectomy. *Surgery* 111, 29-36.
- Harnett, K.M., Cao, W., Biancani, P., 2005. Signal-transduction pathways that regulate smooth muscle function I. Signal transduction in phasic (esophageal) and tonic (gastroesophageal sphincter) smooth muscles. *Am J Physiol Gastrointest Liver Physiol* 288, G407-416.
- Huang, S.C., 2007. Protease-activated receptor-1 (PAR1) and PAR2 but not PAR4 mediate relaxations in lower esophageal sphincter. *Regul Pept* 142, 37-43.
- Ihara, E., Moffat, L., Ostrander, J., Walsh, M.P., MacDonald, J.A., 2007. Characterization of protein kinase pathways responsible for Ca<sup>2+</sup> sensitization in rat ileal longitudinal smooth muscle. *Am J Physiol Gastrointest Liver Physiol* 293, G699-710.
- Kandulski, A., Wex, T., Monkemuller, K., Kuester, D., Fry, L.C., Roessner, A., Malfertheiner, P., 2010. Proteinase-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease. *Am J Gastroenterol* 105, 1934-1943.
- Kawabata, A., Kuroda, R., Nishikawa, H., Kawai, K., 1999. Modulation by protease-activated receptors of the rat duodenal motility in vitro: possible mechanisms underlying the evoked contraction and relaxation. *Br J Pharmacol* 128, 865-872.

- Kawabata, A., Matsunami, M., Sekiguchi, F., 2008. Gastrointestinal roles for proteinase-activated receptors in health and disease. *Br J Pharmacol* 153 Suppl 1, S230-240.
- Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., Yamamori, B., Feng, J., Nakano, T., Okawa, K., Iwamatsu, A., Kaibuchi, K., 1996. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science* 273, 245-248.
- Liu, H., Miller, D.V., Lourensens, S., Wells, R.W., Blennerhassett, M.G., Paterson, W.G., 2010. Proteinase-activated receptor-2 activation evokes oesophageal longitudinal smooth muscle contraction via a capsaicin-sensitive and neurokinin-2 receptor-dependent pathway. *Neurogastroenterol Motil* 22, 210-216, e267.
- Lohman, R.J., Cotterell, A.J., Suen, J., Liu, L., Do, A.T., Vesey, D.A., Fairlie, D.P., 2012. Antagonism of protease-activated receptor 2 protects against experimental colitis. *J Pharmacol Exp Ther* 340, 256-265.
- Mule, F., Baffi, M.C., Cerra, M.C., 2002. Dual effect mediated by protease-activated receptors on the mechanical activity of rat colon. *Br J Pharmacol* 136, 367-374.
- Orel, R., Vidmar, G., 2007. Do acid and bile reflux into the esophagus simultaneously? Temporal relationship between duodenogastro-esophageal reflux and esophageal pH. *Pediatr Int* 49, 226-231.
- Paterson, W.G., Anderson, M.A., Anand, N., 1992. Pharmacological characterization of lower esophageal sphincter relaxation induced by swallowing, vagal efferent nerve stimulation, and esophageal distention. *Can J Physiol Pharmacol* 70, 1011-1015.
- Pfitzer, G., 2001. Invited review: regulation of myosin phosphorylation in smooth muscle. *J Appl Physiol* (1985) 91, 497-503.
- Sekiguchi, F., Hasegawa, N., Inoshita, K., Yonezawa, D., Inoi, N., Kanke, T., Saito, N., Kawabata, A., 2006. Mechanisms for modulation of mouse gastrointestinal motility by proteinase-activated receptor (PAR)-1 and -2 in vitro. *Life Sci* 78, 950-957.
- Shan, J., Oshima, T., Chen, X., Fukui, H., Watari, J., Miwa, H., 2012. Trypsin impaired epithelial barrier function and induced IL-8 secretion through basolateral PAR-2: a lesson from a stratified squamous epithelial model. *Am J Physiol Gastrointest Liver Physiol* 303, G1105-1112.
- Souza, R.F., 2010. Bringing GERD Management up to PAR-2. *Am J Gastroenterol* 105, 1944-1946.
- Strik, M.C., Bladergroen, B.A., Wouters, D., Kisiel, W., Hooijberg, J.H., Verlaan, A.R., Hordijk, P.L., Schneider, P., Hack, C.E., Kummer, J.A., 2002. Distribution of the human intracellular serpin protease inhibitor 8 in human tissues. *J Histochem Cytochem* 50, 1443-1454.

- Vaezi, M.F., Richter, J.E., 1996. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. *Gastroenterology* 111, 1192-1199.
- Vakil, N., van Zanten, S.V., Kahrilas, P., Dent, J., Jones, R., 2006. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 101, 1900-1920; quiz 1943.
- Yoshida, N., Katada, K., Handa, O., Takagi, T., Kokura, S., Naito, Y., Mukaida, N., Soma, T., Shimada, Y., Yoshikawa, T., Okanoue, T., 2007. Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. *Int J Mol Med* 19, 335-340.

### Figure legends

**Fig. 1.** Contractile and relaxant responses to trypsin in the circular smooth muscle of the porcine LES.

A, B, Representative recordings of the contractile and relaxant responses induced by 1  $\mu$ M trypsin (A; n=16) and 10  $\mu$ M trypsin (B; n=15). C, Concentration-dependent responses to trypsin (10 nM – 10  $\mu$ M) are summarized. The level of force is expressed as mN by assigning the level of force at rest in NES to be 0 mN. The data are shown as the mean  $\pm$  S.E.M.

\*P<0.05, \*\*P<0.01 vs. the resting level (0 mN); #P<0.05 vs. contractile force induced by 1  $\mu$ M trypsin

**Fig. 2.** Involvement of PAR<sub>2</sub> in trypsin-induced responses in the circular smooth muscle of the porcine LES.

A-C, Representative recordings of the contractile and relaxant responses to 10  $\mu$ M trypsin in the presence of p-APMSF (A), the contractile responses to human PAR<sub>2</sub>-AP (SLIGKV-NH<sub>2</sub>) (B), and the contractile and relaxant responses to 10  $\mu$ M trypsin in the presence of 10  $\mu$ M FSLLRY-NH<sub>2</sub>, a PAR<sub>2</sub> antagonist (C). D, Summaries of the contractile responses to PAR-APs including PAR<sub>1</sub>-AP (TFLLR-NH<sub>2</sub>) (n=5), mouse PAR<sub>2</sub>-AP (SLIGRL-NH<sub>2</sub>) (n=4), human PAR<sub>2</sub>-AP (SLIGKV-NH<sub>2</sub>) (n=4), AC-264613 (n=4), and PAP<sub>4</sub>-AP (AYPGKF-NH<sub>2</sub>) (n=4). Data are the mean  $\pm$  S.E.M. of the numbers of experiments indicated above. \*\*P<0.01 vs. control. E, Summaries of the effects of PAR<sub>1</sub> antagonist (SCH79797) (n=4) or PAR<sub>2</sub> antagonist (FSLLRY-NH<sub>2</sub>) (n=4) on the contractile and relaxant responses to 10  $\mu$ M trypsin. The resting level of force seen in NES was assigned to be 0 mN. The data are the mean  $\pm$  S.E.M. of the numbers of experiments indicated above. \*P<0.05 vs. control. F, G,



Microscopy images of immunohistochemistry with (F) and without (G) primary antibody, showing PAR<sub>2</sub> expression in the porcine LES. Scale bar indicates 1000  $\mu$ m.

**Fig. 3.** Effects of protein kinase inhibitors on the contractile response to 1  $\mu$ M trypsin in the circular smooth muscle of the porcine LES.

A-F, Representative recordings of contractile response to 1  $\mu$ M trypsin in the presence of 10  $\mu$ M Y-27632 (A; n=7), 1  $\mu$ M H-1152 (B; n=6), 10  $\mu$ M PD98059 (C; n=5), 10  $\mu$ M SB203580 (D; n=4), 10  $\mu$ M GF109203x (E; n=5) and 10  $\mu$ M chelerythrine (F; n=4). G, H, Summaries of the effects of kinase inhibitors on the contractile response to 1  $\mu$ M trypsin, as evaluated by the level of force, while assigning the resting level of force seen just prior to the application of inhibitors to be 0 mN (G) and the net development of force induced by trypsin (H). In G, the lower and upper levels of each column indicate results obtained just prior to trypsin stimulation and at the maximal contraction or at 3 min after trypsin stimulation when no apparent contraction was observed, respectively. The data are the mean  $\pm$  S.E.M. of the numbers of experiments indicated above. \*P<0.05, \*\*P<0.01 vs. control.

**Fig. 4.** Effects of L-NAME, 40 mM K<sup>+</sup> depolarization and K<sup>+</sup> channel blockers on trypsin-induced relaxation in the circular smooth muscle of the porcine LES.

A, B, Representative recordings of the responses induced by 10  $\mu$ M trypsin in the presence of 100  $\mu$ M N<sup>o</sup>-nitro-L-arginine methyl ester (L-NAME) (A; n=5) and 40 mM K<sup>+</sup> (B; n=5). C, D, Summaries of the effects of L-NAME and 40 mM K<sup>+</sup> (C) and K<sup>+</sup> channel blockers (D), including glibenclamide (n=5), 4-aminopyridine (n=4), apamin (n=6) and iberiotoxin (n=4) on trypsin-induced relaxation, as evaluated by the net changes in force induced by trypsin (C,

D). The data are the mean  $\pm$  S.E.M. of the indicated numbers of experiments. \*P<0.05, \*\*P<0.01 vs. control.

**Fig 5.** Effects of protein kinase inhibitors on the biphasic response induced by 10  $\mu$ M trypsin in the circular smooth muscle of the porcine LES.

Representative recordings of contractile and relaxant responses induced by 10  $\mu$ M trypsin in the presence of 10  $\mu$ M Y-27632 (A), 1  $\mu$ M H-1152 (B), 10  $\mu$ M PD98059 (C), 10  $\mu$ M SB203580 (D), 10  $\mu$ M GF109203x (E) and 10  $\mu$ M chelerythrine (F) are shown. The level of force obtained at rest in NES was assigned to be 0 mN.

**Fig. 6.** Summary of effects of protein kinase inhibitors on the biphasic response induced by 10  $\mu$ M trypsin in the circular smooth muscle of the porcine LES.

The summaries of the contractile (A), and relaxant responses (B) induced by 10  $\mu$ M trypsin in the presence of 10  $\mu$ M Y-27632 (n=7), 1  $\mu$ M H-1152 (n=6), 10  $\mu$ M PD98059 (n=7), 10  $\mu$ M SB203580 (n=5), 10  $\mu$ M GF109203x (n=5) and 10  $\mu$ M chelerythrine (n=5), as evaluated by the net changes in force induced by trypsin (A, B). The data are the mean  $\pm$  S.E.M. of the numbers of experiments indicated above. \*P<0.05 vs. control.




Figure1




Figure2




Figure3




Figure4





Figure5

### A contraction



### B relaxation




Figure6